N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action

Journal of Psychiatry and Neuroscience

Volumn 36, Issue 2, 2011, Pages 78-86

  Dean, Olivia ^a,b   Giorlando, Frank ^a,b   Berk, Michael ^a,b,c,d  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Youth Health Orygen Research Centre   (United States)

^d DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DOPAMINE; FLUVOXAMINE; GLUTAMIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADDICTION; ANTIOXIDANT ACTIVITY; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; CANNABIS ADDICTION; COCAINE DEPENDENCE; COMPULSIVE PERSONALITY DISORDER; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HOMEOSTASIS; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGICAL GAMBLING; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; TOBACCO DEPENDENCE; TRICHOTILLOMANIA;

EID: 79953111745     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.100057     Document Type: Review

References (87)

1. Scalley RD, Conner CS. Acetaminophen poisoning: a case report of the use of acetylcysteine. Am J Hosp Pharm 1978;35:964-967.
2. Dodd S, Dean O, Copolov DL, et al. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008;8:1955-1962.
3. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001;57: 1515-7.
4. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003;384:505-516.
5. Meister A. Glutathione, ascorbate, and cellular protection. Cancer Res 1994;54(Suppl):1969s-75s.
6. Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989;6:593-597.
7. Witschi A, Reddy S, Stofer B, et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1992;43:667-669.
8. Vina J, Reginald H, Krebs HA. Maintenance of glutathione content in isolated hepatocytes. Biochem J 1978;170:627-630.
9. Sjodin K, Nilsson E, Hallberg A, et al. Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol 1989;38: 3981-3985.
10. Borgström L, Kågedal B. Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm Drug Dispos 1990;11:131-136.
11. Holdiness MR. Clinical pharmokinetics of N-acetylcysteine. Clin Pharmacokinet 1991;20:123-134.
12. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33:2187-2199.
13. Neuwelt EA, Pagel MA, Hasler BP, et al. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 2001;61:7868-7874.
14. Dean O, van den Buuse M, Copolov D, et al. N-acetylcysteine inhibits depletion of brain glutathione levels in rats: implications for schizophrenia [abstract]. Int J Neuropsychopharmacol 2004; 7(S1):262.
15. Farr SA, Poon HF, Dogrukolak D, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003;84: 1173-1183.
16. Drexhage RC, Knijff EM, Padmos RC, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010;10:59-76.
17. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry 2009;22:32-36.
18. Nascimento MM, Suliman ME, Silva M et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int 2010;30:336-342.
19. Chen G, Shi J, Hu Z et al. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm 2008;2008:716458.
20. Khan M, Sekhon B, Jatana M, et al. Administration of N-acetyl -cysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res 2004;76:519-527.
21. Lante F, Meunier J, Guiramand J, et al. Late N-acetylcysteine treatment prevents the deficits induced in the offspring of dams exposed to an immune stress during gestation. Hippocampus 2008;18: 602-609.
22. Paintlia MK, Paintlia AS, Khan M, et al. Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipo -polysaccharide stimulated mixed glial cultures. J Neurochem 2008; 105:956-970.
23. Janaky R, Dohovics R, Saransaari P, et al. Modulation of [3H]dopamine release by glutathione in mouse striatal slices. Neurochem Res 2007;32:1357-1364.
24. Himi T, Ikeda M, Yasuhara T, et al. Oxidative neuronal death caused by glutamate uptake inhibition in cultured hippocampal neurons. J Neurosci Res 2003;71:679-688.
25. Baker DA, Xi ZX, Shen H, et al. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002;22:9134-9141.
26. Moran MM, McFarland K, Melendez RI, et al. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005;25:6389-6393.
27. Ogita K, Kitago T, Nakamuta H, et al. Glutathione-induced in hibition of Na+-independent and -dependent bindings of L- [3H]glutamate in rat brain. Life Sci 1986;39:2411-2418.
28. Varga V, Jenei Z, Janaky R, et al. Glutathione is an endogenous lig-and of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. Neurochem Res 1997;22:1165-1171.
29. Gere-Paszti E, Jakus J. The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography. Biomed Chromatogr 2009;23:658-664.
30. Hashimoto K, Tsukada H, Nishiyama S, et al. Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine. Ann N Y Acad Sci 2004;1025: 231-235.
31. Gray KM, Watson NL, Carpenter MJ, et al. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010;19:187-189.
32. Knackstedt LA, LaRowe S, Mardikian P, et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009;65:841-845.
33. Van Schooten FJ, Besaratinia A, De Flora S, et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prev 2002;11:167-175.
34. LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006;15:105-110.
35. LaRowe SD, Myrick H, Hedden S, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007;164:1115-1117.
36. Mardikian PN, LaRowe SD, Hedden S, et al. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:389-394.
37. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007;62:652-657.
38. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006;184:254-256.
39. Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol 2007;27:227-229.
40. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009;66:756-763.
41. Berk M, Jeavons S, Dean O, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS Spectr 2009;14:357-360.
42. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glu-tathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:361-368.
43. Bulut M, Savas HA, Altindag A, et al. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry 2009;10:626-628.
44. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468-475.
45. Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008;29:346-351.
46. Kunz M, Gama CS, Andreazza AC, et al. Elevated serum super -oxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1677-1681.
47. Kalivas PW, Lalumiere RT, Knackstedt L, et al. Glutamate transmission in addiction. Neuropharmacology 2009;56(Suppl 1):169-173.
48. Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003;6:743-749.
49. Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psycho -stimulant drugs. Brain Res Rev 2008;58:192-208.
50. Huang MC, Chen CC, Peng FC, et al. The correlation between early alcohol withdrawal severity and oxidative stress in patients with alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:66-69.
51. Pereska Z, Dejanova B, Bozinovska C, et al. Prooxidative/antioxidative homeostasis in heroin addiction and detoxification. Bratisl Lek Listy 2007;108:393-398.
52. Madayag A, Lobner D, Kau KS, et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007;27:13968-13976.
53. Chen HH, Stoker A, Markou A. The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology (Berl) 2010;209:343-350.
54. Huey ED, Zahn R, Krueger F, et al. A psychological and neuroanatomical model of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2008;20:390-408.
55. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsycho -pharmacology 2010;35:217-238.
56. Kuloglu M, Atmaca M, Tezcan E, et al. Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder. Neuropsychobiology 2002;46:27-32.
57. Chakraborty S, Singh OP, Dasgupta A, et al. Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:363-366.
58. Ersan S, Bakir S, Erdal Ersan E, et al. Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1039-1042.
59. Ozdemir E, Cetinkaya S, Ersan S, et al. Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:62-65.
60. Selek S, Herken H, Bulut M, et al. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:487-491.
61. Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 2010;15:850-855.
62. Carlsson ML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:5-26.
63. Dell'Osso B, Altamura AC, Allen A, et al. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci 2006;256:464-475.
64. Hautmann G, Hercogova J, Lotti T. Trichotillomania. J Am Acad Dermatol 2002;46:807-821, quiz 22-6.
65. Bloch MH. Trichotillomania across the life span. J Am Acad Child Adolesc Psychiatry 2009;48:879-883.
66. Grant JE, Odlaug BL, Potenza MN. Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome. Harv Rev Psychiatry 2007;15:80-85.
67. Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001;41:237-260.
68. Marek GJ, Behl B, Bespalov AY, et al. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain? Mol Pharmacol 2010;77:317-326.
69. Oja SS, Janaky R, Varga V, et al. Modulation of glutamate receptor functions by glutathione. Neurochem Int 2000;37:299-306.
70. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006;39(Suppl 1):S10-14.
71. Dean OM, van den Buuse M, Bush AI, et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009; 16:2965-2976.
72. Raffa M, Mechri A, Othman LB, et al. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009;33: 1178-1183.
73. Pazvantoglu O, Selek S, Okay IT, et al. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci 2009;63:693-700.
74. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11:851-876.
75. Carter CJ. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 2006;86:1-14.
76. Berk M, Munib A, Dean O et al. Qualitative methods in early-phase drug trials: data and methods from a trial of N-acetyl cys-teine in schizophrenia. J Clin Psychiatry 2010 Sep. 1 [Epub ahead of print].
77. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008;111:135-144.
78. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 2009;34:263-271.
79. Palmer LA, Doctor A, Chhabra P, et al. S-Nitrosothiols signal hypoxia- mimetic vascular pathology. J Clin Invest 2007;117:2592-2601.
80. Devi PU, Pillai KK, Vohora D. Facilitation action of N-acetylcysteine on the anticonvulsant effect of sodium valproate in mice. Basic Clin Pharmacol Toxicol 2006;98:521-522.
81. Bailey B, Blais R, Letarte A. Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death. Ann Emerg Med 2004;44:401-406.
82. Kau KS, Madayag A, Mantsch JR, et al. Blunted cystine-glutamate an-tiporter function in the nucleus accumbens promotes cocaine-induced drug seeking. Neuroscience 2008;155:530-537.
83. Baker DA, McFarland K, Lake RW, et al. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci 2003; 1003: 349-351.
84. Moussawi K, Pacchioni A, Moran M, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci 2009;12:182-189.
85. Bian Q, Kato T, Monji A, et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:42-48.
86. Bai O, Chlan-Fourney J, Bowen R, et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003;71:127-131.
87. Pillai A, Parikh V, Terry AV Jr, et al. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typ -ical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007;41:372-386.